Abstract:Objective To investigate the immune response against Hepatitis B virus (HBV) in- duced by HBsAg recombinant adenovirus (Ad-S)-transduced dendritic cells (DCs) in HBV transgenic mice (HBV-Tg),and evaluate its potential in treating chronic HBV infection.Methods DCs were generated from bone marrow cells from the HBV Tg mice.and transfected with Ad-S (DC/Ad-S) or pulsed with HBsAg protein (DC/HBsAg).HBV-Tg mice were randomly assigned to receive either DC/Ad-S (n=10) or DC/HBsAg(n=10) or pcDNA3.1(+) S plasmid (n=6),and the same im munization schedule was repeated twice at 3 week intervals.Intracellular cytokines of splenic T cells, HBsAg-specific activity of splenic cytotoxic T lymphocyte (CTL),and HBsAg and anti-HBs and HBV DNA titers in sera were detected after immunization by flow eytometry,LDH release assay, ELISA and quantitative PCR,respectively.Hepatic injury was monitored at various time points after immunization by measuring serum alanine aminotransferase (ALT) activity.Tissue samples of the liver were stained with hematoxylin and eosin for histological analysis,and the expression of hepatitis B core Ag(HBcAg) and HBsAg was assessed by immunohistochemical analysis.Results DC/Ad-S stimulated splenic Tc more efficiently to secrete IFNγthan DC/HBsAg or pcDNA3. 1 (+)-S (P＜0.05 or P＜0.01),and induced stronger splenic HBsAg-specific CTL responses than that induced by DC/HBsAg (P＜0.05 or P＜0.01 at 10:1,20:1,40:1 of E:T ratio),which were stronger than that induced by DNA vaccination (all P＜0.01 at 10:1,20:1,40:1 of E:T ratio),at 1 or 2 weeks after immunization, respectively. The CTL response elicited by DC/Ad-S was transient, rising to strongest at 1 to 2 weeks after immunization and waning gradually thereafter,but reduced more slowly than that elicited by DC/HBsAg.The suppression of serum HBsAg and HBV DNA and the reduction of expression of HBcAg and HBsAg in liver from HBV-Tg mice induced by DC/Ad-S were the strongest in all groups of immunization,and the second was that induced by DC/HBsAg from 1 to 4 weeks after immunization.The serum anti-HBs titer and ALT activity were slightly elevated,and histological analysis of the liver displayed only a very slight focal inflammatory infiltration up to 4 weeks after immunization,and the inter-group differences were not significant.Conclusions HBsAg recombinant adenovirus-transduced DCs can induce Tcl and CTL response,reduce the titer of serum HBsAg and HBV DNA,and inhibite the expression of HBcAg and HBsAg in liver in HBV-Tg mice, stronger than that induced by HBsAg-pulsed DCs or plasmid DNA.

Oral vaccination of mice with Tremella fuciformis yeast-like conidium cells expressing HBsAg

Immune Response Against Hepatitis B Virus Induced by HBsAg Recombinant Adenovirus-Transduced Dendritic Cells in BALB/c Mice

TBK-1 Enhances Humoral and Cellular Immune Responses in Mice Induced by DNA Vaccination of HBV Core Gene

[Induction of Immune Responses in Mice by Hepatitis B Virus Large Envelope DNA Vaccine Delivered by Attenuated Salmonella Typhimurium].

Study on the Immune Response Induced by Hbcag Gene-Modified Dendritic Cells in Hepatitis B Virus Transgenic Mice

Whole Recombinant Hansenula Polymorpha Expressing Hepatitis B Virus Surface Antigen (Yeast-Hbsag) Induces Potent HBsAg-specific Th1 and Th2 Immune Responses.

Immunization with HBsAg-Fc Fusion Protein Induces a Predominant Production of Th1 Cytokines and Reduces HBsAg Level in Transgenic Mice.

[The Immunization Effects of HBV Core Antigen and Surface Antigen Fusion Protein in Mice].

Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

[Impact of Different Adjuvants on Immunogenicity of the HBV Particle Vaccine Containing the S + Pres1 Fusion Antigen in Balb/C Mice].

DNA-based Vaccination Induces Humoral and Cellular Immune Responses Against Hepatitis B Virus Surface Antigen in Mice Without Activation of C-myc.

Oral Immunization of Animals with Transgenic Cherry Tomatillo Expressing Hbsag

Immune Responses Elicited by Oral DNA Vaccine of Hepatitis C Virus Fusion Antigen in Mice

Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.

Mannosylated and Lipid A-Incorporating Cationic Liposomes Constituting Microneedle Arrays As an Effective Oral Mucosal Hbv Vaccine Applicable in the Controlled Temperature Chain

Effect of Plasmid DNA on Immunogenicity of HBsAg–Anti-HBs Complex

Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route

Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant

Robust Immune Responses Elicited By A Hybrid Adjuvant Based On Beta-Glucan Particles From Yeast For The Hepatitis B Vaccine

Augmented humoral and cellular immune response of hepatitis B virus DNA vaccine by micro-needle vaccination using Flt3L as an adjuvant

The Oral Vaccination of HBV by Cherry Tomatillo transformed with HBsAg